<DOC>
	<DOCNO>NCT01543971</DOCNO>
	<brief_summary>This Phase I Study conduct 18 healthy volunteer . Each receive daily injection 5 day TXA127 alone , Neupogen alone , TXA127 plus Neupogen together . The aim study determine safety TXA127 alone combination Neupogen , determine whether use TXA127 alone combination Neupogen enhance peripheral blood stem cell ( CD34+ ) mobilization .</brief_summary>
	<brief_title>Safety Efficacy TXA127 Neupogen Increase Peripheral Blood Stem Cells ( PBSCs )</brief_title>
	<detailed_description>In double-blinded comparison study , healthy volunteer randomize one 3 treatment group : ( Group A ) TXA127 300 mcg/kg day 5 day ( Group B ) Neupogen 10 mcg/kg day 5 day ( Group C ) together day 5 day , treatment administer subcutaneous injection , increase peripheral blood stem cell ( CD34+ ) concentration healthy volunteer . A minimum 18 healthy male female volunteer Subjects ( 6 treatment group ) meet inclusion none exclusion criterion enrol study . Subjects recruit study center 's exist database healthy volunteer and/or advertising . A sufficient number alternate volunteer screen checked-in Day 0 ensure 6 eligible healthy volunteer enrol Day 1 treatment group . Subjects remain housed teh Unit conduct study . Safety : Predose blood sample collect immediately prior receive study medication ( ) , well 4 hour , 8 hour , 12 hour 16 hour post-dose .</detailed_description>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<criteria>Volunteer capable reading , understand comply protocol , informed nature risk study participation sign informed consent document prior undergo study related procedure . Volunteer male female 18 45 year age , inclusive . If female , must nonlactating negative serum pregnancy test result screen admission . Must good health must weigh least 45 kg , 90 kg Body Mass Index ( BMI ) 17.5 kg/m2 35 kg/m2 . Screening admission clinical laboratory test result within lab 's reference range , , consider clinically significant Investigator . Screening admission 12lead electrocardiogram ( ECGs ) normal , abnormal , consider clinically significant Investigator . Have negative urine drug alcohol toxicology screen screen admission , negative HIV antibody hepatitis panel result screen . History acute chronic medical condition test abnormality would significantly increase Volunteer 's risk study participation significantly increase risk achieve study objective , Investigator 's opinion . Has know suspect liver disease ( active hepatitis , cirrhosis , hepatic insufficiency ascites ) transaminase value &gt; 2x ULN total bilirubin &gt; 1.5 x ULN , history spleen enlargement , except due infectious mononucleosis resolve 6 month prior schedule admission , current find spleen enlargement . Has history mononucleosis within previous six month schedule admission . Has abnormally low Protein C Protein S screening , screen laboratory test indicate Factor V Leiden present . Has history venous thrombosis pulmonary embolism , systolic blood pressure persistently &gt; 145 mm Hg &lt; 90 mm Hg , diastolic blood pressure persistently &gt; 90 mm Hg &lt; 60 mm Hg screen admission . Has heart rate persistently &gt; 90 beats/minute &lt; 45 beats/minute vital sign test screen admission , 10second ECG Screening , Admission Baseline ( prior first dose ) show follow : HR &lt; 45 &gt; 90 bpm ; QRS interval &gt; 120 msec ; PR interval &lt; 120 &gt; 220 msec ; QTcF &lt; 300 msec &gt; 450 msec ; Any fascicular block bundle branch block ; Neuromuscular ECG artifact readily eliminate . Has history substance abuse , drug addiction , alcoholism within 1 year prior screening . ( As define DSM IV criterion ) . Within 2 week prior schedule administration study drug , Volunteer take prescription overthecounter medication , herbal preparation dietary supplement , opinion Investigator , may increase risk Volunteer 's safety achievement study objective . Unwilling abstain alcohol use caffeine 24 hour prior admission . Has donate blood blood product within 30 day prior admission ; consider mentally unstable exhibit anxious , excitable , hostile , emotionally reactive affect ; receive investigational test substance within 30 day prior schedule administration investigational test article , anticipate receive investigational test substance TXA127 course study . Volunteer previously participate clinical study TXA127 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Peripheral blood stem cell mobilization</keyword>
	<keyword>CD34+ count</keyword>
</DOC>